CHICAGO, October 08, 2025--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered ...

VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for safer, more efficient, and more scalable ...

CHICAGO--(BUSINESS WIRE)--#BioTechNews--VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for ...

ROCKVILLE, Md., Oct. 8, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, today announced that its European patent EP3722434, protecting EpyQ®, the company's ...

This important study presents a thoughtful design and characterization of chimeric influenza hemagglutinin (HA) head domains combining elements of distinct receptor-binding sites. The results provide ...

The Company treated the first patient in the pivotal Phase 3 OVATION 3 Study in July 2025 and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have ...

IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per planLAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ...

Fourth-year biomedical engineering candidate Yining Zhu has been named a 2026 Siebel Scholar, an honor that recognizes students in bioengineering fields for exemplary achievement in academia, research ...

UNLV scientists successfully introduced nanoparticles with messenger RNA into the pancreas for the first time with 99% accuracy.

This article examines key innovations driving scalable, high-yield purification of recombinant AAVs and how they’re helping ...

The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2025, more than 1,300, including many clinical based Late-breaking Abstracts. SITC is proud to ...